Bisphosphonates in the Management of Metastatic Prostate Cancer
Axel Heidenreich
Department of Urology, Philipp University Marburg, Marburg, Germany
Oncology 2003;65 (Suppl. 1):5-11 (DOI: 10.1159/000072485)
Key Words
- Prostate cancer
- Zoledronate
- Ibandronate
- Androgen deprivation
- Osteoporosis
- Palliation
- Pain management
Abstract
Prostate cancer (PCA) frequently metastasizes to the bones, and skeletal metastases represent the most common cause of morbidity in advanced PCA. Besides the development of skeletal events due to metastases, patients with PCA are at higher risk for benign osseous complications, such as osteoporosis and fractures. Bisphosphonates (BPs) have emerged as an integral part of the management of skeletal disease related to PCA. Currently available data support their routine use to prevent androgen-deprivation-induced osteoporosis and its secondary complications. Dosing at 3-month intervals is appropriate; further studies will have to demonstrate the efficacy of annual dosing. In men with already established bone metastases, BPs might be helpful in preventing skeletal-related events in patients who do not respond to alternative therapies and are at high risk for bone fractures or spinal cord compression. In patients with hormone-refractory prostate cancer, BPs might be administered for analgesic purposes. Prospective randomized trials will have to explore the clinical role of BPs in the prevention of bone metastases following local therapy with curative intent in men at high risk for PCA recurrences.
Copyright © 2003 S. Karger AG, Basel
Author Contacts
Priv. Doz. Dr.med. Axel Heidenreich, Associate Professor of Urology
Department of Urology and Pediatric Urology, Philipps University Marburg
Baldingerstrasse, DE-35043 Marburg (Germany)
Tel. +49 6421 286 2514, Fax +49 6421 286 5590
E-Mail heidenre@post.med.uni-marburg
No comments:
Post a Comment